# Triptolide payloads

Source: https://onco.cc/terms/triptolide-payloads/  
OnCo record `triptolide-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Triptolide payloads interfere with the cell's ability to make messages from its genes. An antibody-linked version has been studied in cancer cells and mice.

## Summary

Y-TR1 combines the CD26-directed antibody YS110 with a triptolide derivative that inhibits the general transcription factor TFIIH. The published study reported altered RNA synthesis and antitumor activity in CD26-positive experimental models. This is preclinical evidence for a transcription-directed conjugate, not evidence that triptolide is an established antibody payload in clinical care.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: TFIIH inhibitor payloads; Y-TR1; Y-TR-1

## Sources

- Hayashi et al., Y-TR1 transcription-inhibitor conjugate (2019): https://doi.org/10.3390/cancers11081138

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/), [Transcription-inhibitor payloads](https://onco.cc/terms/transcription-inhibitor-payloads/)

---
JSON: https://onco.cc/api/v1/entities/triptolide-payloads.json